Marine algal polysaccharides as future potential constituents against non-alcoholic steatohepatitis

被引:9
|
作者
Lu, Si-Yuan [1 ,3 ]
Tan, Karsoon [2 ]
Zhong, Saiyi [1 ]
Cheong, Kit -Leong [1 ,3 ]
机构
[1] Guangdong Ocean Univ, Coll Food Sci & Technol, Guangdong Prov Key Lab Aquat Prod Proc & Safety, Zhanjiang, Peoples R China
[2] Beibu Gulf Univ, Guangxi Key Lab Beibu Gulf Biodivers Conservat, Qinzhou, Guangxi, Peoples R China
[3] Shantou Univ, Coll Sci, Dept Biol, Guangdong Prov Key Lab Marine Biotechnol, Shantou, Guangdong, Peoples R China
关键词
NASH; Functional food; Seaweeds; LIVER-KIDNEY FUNCTIONS; AROMATIC-AMINO-ACIDS; SULFATED POLYSACCHARIDES; GUT MICROBIOTA; HEPATOCELLULAR-CARCINOMA; PHYSICOCHEMICAL PROPERTIES; UNDARIA-PINNATIFIDA; INSULIN-RESISTANCE; OXIDATIVE STRESS; FUCOIDAN;
D O I
10.1016/j.ijbiomac.2023.126247
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Non-alcoholic steatohepatitis (NASH) is one of the most chronic and incurable liver diseases triggered mainly by an inappropriate diet and hereditary factors which burden liver metabolic stress, and may result in liver fibrosis or even cancer. While the available drugs show adverse side effects. The non-toxic bioactive molecules derived from natural resources, particularly marine algal polysaccharides (MAPs), present significant potential for treating NASH. In this review, we summarized the protective effects of MAPs on NASH from multiple perspectives, including reducing oxidative stress, regulating lipid metabolism, enhancing immune function, preventing fibrosis, and providing cell protection. Furthermore, the mechanisms of MAPs in treating NASH were comprehensively described. Additionally, we highlight the influences of the special structures of MAPs on their bioactive differences. Through this comprehensive review, we aim to further elucidate the molecular mechanisms of MAPs in NASH and inspire insights for deeper research on the functional food and clinical applications of MAPs.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Non-Alcoholic Steatohepatitis in Healthy Potential Liver Donors
    Jothimani, Dinesh
    Govil, Sanjay
    Vij, Mukul
    Narasimhan, Gomathy
    Rela, Mohamed
    TRANSPLANTATION, 2016, 100 : S185 - S185
  • [22] Current, emerging, and potential therapies for non-alcoholic steatohepatitis
    Yang, Zhen
    Wang, Lin
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [23] Outcomes and potential surrogate markers for future clinical trials of non-alcoholic steatohepatitis cirrhosis
    Rivera-Esteban, Jesus
    Armandi, Angelo
    Augustin, Salvador
    Bugianesi, Elisabetta
    LIVER INTERNATIONAL, 2021, 41 (09) : 1999 - 2008
  • [24] Src kinase as a potential therapeutic target in non-alcoholic and alcoholic steatohepatitis
    Kurniawan, Dhadhang Wahyu
    Booijink, Richell
    Jajoriya, Arun Kumar
    Dhawan, Garima
    Mishra, Divya
    Oosterhuis, Dorenda
    Argemi, Josepmaria
    Storm, Gert
    Olinga, Peter
    Bataller, Ramon
    Mohanty, Sujit Kumar
    Mishra, Durga Prasad
    Prakash, Jai
    Bansal, Ruchi
    CLINICAL AND TRANSLATIONAL DISCOVERY, 2022, 2 (01):
  • [25] Drugs and non-alcoholic steatohepatitis
    Farrell, GC
    STEATOHEPATITIS (NASH AND ASH), 2001, 121 : 132 - 139
  • [26] Obesity and non-alcoholic steatohepatitis
    García-Monzón, C
    STEATOHEPATITIS (NASH AND ASH), 2001, 121 : 117 - 123
  • [27] Saroglitazar for non-alcoholic steatohepatitis
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (09): : 698 - 698
  • [28] Mechanisms of non-alcoholic steatohepatitis
    McClain, CJ
    Mokshagundam, PL
    Barve, SS
    Song, ZY
    Hill, DB
    Chen, T
    Deaciuc, I
    ALCOHOL, 2004, 34 (01) : 67 - 79
  • [29] Metformin in non-alcoholic steatohepatitis
    Marchesini, G
    Brizi, M
    Bianchi, G
    Tomassetti, S
    Zoli, M
    Melchionda, N
    LANCET, 2001, 358 (9285): : 893 - 894
  • [30] Selonsertib for non-alcoholic steatohepatitis
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (12): : 852 - 852